AI Article Synopsis
- CDKs are essential for cell growth and are hijacked by both DNA and RNA viruses to boost their replication.
- New pharmacological CDK inhibitors, initially developed for cancer treatment, may be repurposed as antiviral therapies.
- The review highlights the mechanisms of CDKs, their potential as drug targets, and examines the current progress on these inhibitors in treating viral infections, particularly emerging ones.*
Article Abstract
Besides its prominent role in cell proliferation, cyclin-dependent kinases (CDKs) are key players in viral infections as both DNA and RNA viruses modify CDK function to favor viral replication. Recently, a number of specific pharmacological CDK inhibitors have been developed and approved for cancer treatment. The repurposing of these specific CDK inhibitors for the treatment of viral infections may represent a novel effective therapeutic strategy to combat old and emergent viruses. In this review, we describe the role, mechanisms of action, and potential of CDKs as antiviral drug targets. We also discuss the current clinical state of novel specific CDK inhibitors, focusing on their putative use as antivirals, especially against new emerging viruses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tim.2021.01.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!